Literature DB >> 20132994

Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.

Valéria Marçal Felix de Lima1, Fabiana Augusta Ikeda, Cláudio N Rossi, Mary Marcondes Feitosa, Rosemeride Oliveira Vasconcelos, Caris Maroni Nunes, Hiro Goto.   

Abstract

The Leishmune vaccine has been used in endemic areas to prevent canine visceral leishmaniasis in Brazil, but cytokine production induced by vaccination has rarely been investigated in dogs. This study aimed to evaluate the immune response of dogs vaccinated with Leishmune FML vaccine (Fort Dodge) against total antigen of Leishmania (Leishmania) chagasi (TAg) and FML. Twenty healthy dogs from Araçatuba, São Paulo, Brazil, an endemic leishmaniasis area, received three consecutive subcutaneous injection of Leishmune vaccine at 21-day intervals. PBMC were isolated before and 10 days after completing vaccination and lymphoproliferative response and antibody production against FML or total promastigote antigen were tested. Cytokines IFN-gamma, IL-4 and TNF-alpha were measured in culture supernatant and CD4+/CD25+ and CD8+/CD25+ T cell presence was determined. Analysis of the data indicated that the vaccine conferred humoral responses (100%) against both antigens and cellular immunity to FML (85%) and total antigen (80%), the supernatant of cultured cells stimulated with TAg and FML showed an increase in IFN-gamma (P<0.05), and the vaccine reduced CD4+/CD25+ T cell presence compared to that observed before vaccination. These responses may constitute part of the immune mechanism induced by Leishmune. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132994     DOI: 10.1016/j.vetimm.2009.12.008

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  11 in total

Review 1.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

Review 2.  Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.

Authors:  Ana Nieto; Gustavo Domínguez-Bernal; José A Orden; Ricardo De La Fuente; Nadia Madrid-Elena; Javier Carrión
Journal:  Vet Res       Date:  2011-02-23       Impact factor: 3.683

Review 3.  The immunopathology of canine vector-borne diseases.

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

Review 4.  One Health: the global challenge of epidemic and endemic leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa; Michael J Day
Journal:  Parasit Vectors       Date:  2011-10-10       Impact factor: 3.876

Review 5.  Vaccines for canine leishmaniasis.

Authors:  Faeze Foroughi-Parvar; Gholamreza Hatam
Journal:  Adv Prev Med       Date:  2014-12-31

Review 6.  Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.

Authors:  Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

7.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

8.  Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Iam Palatnik-de-Sousa; Alexandre Morrot; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-06-11       Impact factor: 7.561

9.  Cytokine profile and nitric oxide levels in peritoneal macrophages of BALB/c mice exposed to the fucose-mannose ligand of Leishmania infantum combined with glycyrrhizin.

Authors:  Hasan Namdar Ahmadabad; Reza Shafiei; Gholam Reza Hatam; Reza Zolfaghari Emameh; Ashok Aspatwar
Journal:  Parasit Vectors       Date:  2020-07-20       Impact factor: 3.876

Review 10.  The Delay in the Licensing of Protozoal Vaccines: A Comparative History.

Authors:  Clarisa Beatriz Palatnik-de-Sousa; Dirlei Nico
Journal:  Front Immunol       Date:  2020-03-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.